Literature DB >> 9155585

Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease.

R S Walmsley1, M H Zhao, M I Hamilton, A Brownlee, P Chapman, R E Pounder, A J Wakefield, C M Lockwood.   

Abstract

BACKGROUND: Bactericidal/permeability-increasing protein (BPI), a constituent of primary neutrophil granules, is a potent natural antibiotic and an antineutrophil cytoplasm antibody (ANCA) antigen in cases of vasculitis in which the target antigen is neither myeloperoxidase (MPO) nor proteinase-3 (PR3). AIM: To investigate BPI as a possible target antigen for ANCAs in inflammatory bowel disease.
METHODS: ANCAs were detected by routine immunofluorescence (IIF) and solid phase enzyme linked immunosorbent assay (ELISA) performed for antibodies to the purified neutrophil granule proteins; MPO, PR3, cathepsin-G, lactoferrin, and BPI in serum samples from 88 patients with inflammatory bowel disease (36 with Crohn's disease, 52 with ulcerative colitis). Thirty patients with bacterial enteritis acted as controls.
RESULTS: Significantly more patients with ulcerative colitis were ANCA positive by IIF (60%) than patients with Crohn's disease (28%) or infectious enteritis (23%) (p < 0.001). IgG anti-BPI antibodies were present in 29% of patients with ulcerative colitis, 14% of patients with Crohn's disease, and 23% of patients with infectious enteritis, occurring in 44% of those patients with inflammatory bowel disease who were ANCA positive by IIF. Antibodies to other ANCA antigens were rare. The presence of ANCAs was not related to either disease activity or extent; presence of anti-BPI antibodies was significantly related to both a lower serum albumin concentration (p = 0.001) and a higher erythrocyte sedimentation rate (p = 0.02) in patients with ulcerative colitis, and to colonic involvement in patients with Crohn's disease (p = 0.01).
CONCLUSION: BPI is a significant minority target antigen for ANCAs in inflammatory bowel disease that seems related to colonic Crohn's disease and disease activity in ulcerative colitis. Anti-BPI antibodies occur in infectious enteritis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9155585      PMCID: PMC1027017          DOI: 10.1136/gut.40.1.105

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  25 in total

1.  An index of disease activity in patients with ulcerative colitis.

Authors:  M Seo; M Okada; T Yao; M Ueki; S Arima; M Okumura
Journal:  Am J Gastroenterol       Date:  1992-08       Impact factor: 10.864

2.  Significance of systemic endotoxaemia in inflammatory bowel disease.

Authors:  K R Gardiner; M I Halliday; G R Barclay; L Milne; D Brown; S Stephens; R J Maxwell; B J Rowlands
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

3.  Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment.

Authors:  M Oudkerk Pool; P M Ellerbroek; B U Ridwan; R Goldschmeding; B M von Blomberg; A S Peña; K M Dolman; H Bril; W Dekker; J J Nauta
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

4.  Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis.

Authors:  M H Zhao; S J Jones; C M Lockwood
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

5.  Antibacterial proteins of granulocytes differ in interaction with endotoxin. Comparison of bactericidal/permeability-increasing protein, p15s, and defensins.

Authors:  O Levy; C E Ooi; P Elsbach; M E Doerfler; R I Lehrer; J Weiss
Journal:  J Immunol       Date:  1995-05-15       Impact factor: 5.422

6.  Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders.

Authors:  M P Stoffel; E Csernok; C Herzberg; T Johnson; S F Carroll; W L Gross
Journal:  Clin Exp Immunol       Date:  1996-04       Impact factor: 4.330

7.  The presence of peptidoglycan-polysaccharide complexes in the bowel wall and the cellular responses to these complexes in Crohn's disease.

Authors:  I S Klasen; M J Melief; A G van Halteren; W R Schouten; M van Blankenstein; G Hoke; H de Visser; H Hooijkaas; M P Hazenberg
Journal:  Clin Immunol Immunopathol       Date:  1994-06

8.  Bactericidal/permeability-increasing protein protects vascular endothelial cells from lipopolysaccharide-induced activation and injury.

Authors:  M Arditi; J Zhou; S H Huang; P M Luckett; M N Marra; K S Kim
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

9.  Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis.

Authors:  M H Zhao; D R Jayne; L G Ardiles; F Culley; M E Hodson; C M Lockwood
Journal:  QJM       Date:  1996-04

10.  Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease.

Authors:  Y Liu; H J van Kruiningen; A B West; R W Cartun; A Cortot; J F Colombel
Journal:  Gastroenterology       Date:  1995-05       Impact factor: 22.682

View more
  22 in total

Review 1.  A neutrophil-derived anti-infective molecule: bactericidal/permeability-increasing protein.

Authors:  O Levy
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

Review 2.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

3.  IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis.

Authors:  C Schwarze; B Terjung; P Lilienweiss; U Beuers; V Herzog; T Sauerbruch; U Spengler
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

Review 4.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

5.  Ulcerative colitis and perinuclear antineutrophil cytoplasmic antibodies.

Authors:  P C Doré
Journal:  J Clin Pathol       Date:  1998-04       Impact factor: 3.411

6.  Catalase and alpha-enolase: two novel granulocyte autoantigens in inflammatory bowel disease (IBD).

Authors:  C Roozendaal; M H Zhao; G Horst; C M Lockwood; J H Kleibeuker; P C Limburg; G F Nelis; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

7.  Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative colitis.

Authors:  H Locht; T Skogh; A Wiik
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

8.  Bactericidal/permeability increasing protein gene polymorphism and inflammatory bowel diseases: meta-analysis of five case-control studies.

Authors:  Lijuan Fan; Guoning Fu; Yuanyuan Ding; Peng Lv; Hongyun Li
Journal:  Int J Colorectal Dis       Date:  2016-12-30       Impact factor: 2.571

9.  Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy.

Authors:  B Terjung; H J Worman; V Herzog; T Sauerbruch; U Spengler
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

Review 10.  Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"?

Authors:  Birgit Terjung; Ulrich Spengler
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.